Why the study?
Sufficient and consistent research data are lacking regarding Kawasaki disease diagnosis, prognostication using renin-angiotensin system biomarkers, and treatment with ACE inhibitors or ARBs.
Current evidence is insufficient to routinely recommend ACE inhibitors or ARBs for Kawasaki disease, though guidelines suggest they may be considered in patients with coronary artery aneurysms.
Answers are grounded in this paper and cite their sources.
RAS biomarkers may aid Kawasaki diagnosis/prognostication; leaves open clinical adoption without validation.
The renin-angiotensin system plays a crucial role in maintaining homeostasis of the cardiovascular system, and there have been studies on its relevance to the onset of Kawasaki disease and coronary artery complications. However, there is still a lack of sufficient and consistent research data regarding the diagnosis and prognostication of Kawasaki disease using the genetic/serologic biomarkers associated with this system. The use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers as therapeutic agents also lacks substantial experimental and clinical evidence. According to the JCS/JSCS guideline, in the case of patients with coronary artery aneurysms, the use of these medications in combination with other conventional treatments could be considered with the consent of the patient/guardians.
No takes yet. Share an insight, caveat, or question.
Jeong Jin Yu (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: